Silenor Shortage Update: What Patients Need to Know in 2026

If you've been searching for Silenor (doxepin) at pharmacies near you and coming up empty, you may be wondering: is there an official shortage? The short answer in 2026 is no — but the situation is more nuanced than a simple "yes" or "no."

Is There an Official Silenor Shortage in 2026?

As of 2026, Silenor (doxepin tablets for insomnia) is not listed on the FDA's official drug shortage database, nor does the American Society of Health-System Pharmacists (ASHP) have an active shortage alert for low-dose doxepin tablets.

This means there is no documented supply chain failure, manufacturing halt, or raw material shortage affecting Silenor. The medication is being produced and distributed.

So Why Are Patients Struggling to Find It?

Even without a formal shortage, patients frequently report difficulty finding Silenor. The reasons relate to demand, stocking economics, and market dynamics rather than a supply disruption:

Low prescription volume: Silenor is not among the most commonly prescribed sleep medications. Pharmacies prioritize shelf space for high-volume drugs.

Brand vs. generic confusion: Generic doxepin low-dose tablets became available in 2020. Many pharmacies stock the generic but not brand Silenor. If your prescription specifies the brand, your pharmacy may not have it.

High retail cost of brand Silenor: Brand Silenor costs $500–$650/month without insurance. Most insurers require prior authorization or step therapy. This reduces demand for the brand and therefore pharmacy stocking.

Market consolidation: As of 2026, many patients who were on brand Silenor have switched to generic doxepin tablets or alternative sleep aids, further reducing the number of dispensing pharmacies.

History of Silenor Availability

Silenor was first FDA-approved in March 2010, originally sold by Somaxon Pharmaceuticals, later acquired by Currax Pharmaceuticals. The drug represented a novel application of an old compound — doxepin, a tricyclic antidepressant approved since 1969 — at a fraction of the antidepressant dose.

By 2020, generic versions of low-dose doxepin tablets entered the market. A 2025 JAMA study noted that in 2023, generic low-dose doxepin tablets accounted for 97% of all low-dose doxepin fills, while brand Silenor accounted for just 3,019 thirty-day supplies — a fraction of the market.

The Silenor manufacturer copay program (which reduced cost to $25 for eligible patients) ended in 2023, making brand Silenor even less accessible for patients without comprehensive insurance coverage.

What This Means for Patients in 2026

If you have a Silenor prescription, here's what you should know:

There is no active shortage — the medication exists and is being produced.

Brand Silenor may not be stocked at many pharmacies — but generic doxepin tablets (same drug) are more commonly available.

Insurance may make brand Silenor difficult — prior authorization is commonly required. Generic doxepin tablets are usually covered without these barriers.

Your best solution in most cases is switching to generic doxepin — ask your doctor to write for it specifically.

What to Do Right Now

Ask your doctor to prescribe generic doxepin 3 mg or 6 mg tablets instead of brand Silenor.

Call independent pharmacies in your area and ask if they can special-order Silenor or generic doxepin tablets.

Use medfinder to find which pharmacies near you currently have the medication in stock.

Check your insurance coverage for generic doxepin — it is typically Tier 1 with no prior authorization required.

Will Silenor Availability Get Better or Worse?

Without an active shortage, availability of generic doxepin tablets is expected to remain stable in 2026. Multiple generic manufacturers produce low-dose doxepin tablets. Brand Silenor's availability depends on Currax Pharmaceuticals' distribution decisions; demand for the brand is expected to remain low given generic competition.

For more background, see: Why Is Silenor So Hard to Find? [Explained for 2026].